The Korean Journal of Adult Nursing (KJAN) is the official peer-reviewed research journal of the Korean Society of Adult Nursing (KSAN). KJAN is devoted to the dissemination of groundbreaking research on theory, practice, and education in the field of adult nursing. Research on other subject areas or issues that contribute to adult nursing is published at the discretion of the Editorial Board. The goal of KJAN is to contribute to health maintenance, health promotion, and disease prevention and management in adults by publishing research. KJAN is published four times per year at the end of February, May, August, and November.
For policies on research and publication ethics that are not stated in these instructions, the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals by the International Committee of Medical Journal Editors (ICMJE) or the COPE Guidelines (https://publicationethics.org/guidance/Guidelines) can be applied. Further, all processes of handling research and publication misconduct shall follow the applicable COPE flowchart.
Statements of human and animal rights: Clinical research should be done in accordance with the Ethical Principles for Medical Research Involving Human Subjects, outlined in the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). Any study involving human subjects or human data must be reviewed and approved by a responsible institutional review board (IRB). Research involving meta-analyses, systematic reviews, and literature reviews does not require IRB review. For secondary data analyses, IRB review and approval for an exempt study may be required based on the decision of the Editorial Board. When necessary, the Editorial Board may request any documentation regarding ethical issues of the manuscript such as written consent or the approval of the study by the IRB. Furthermore, for studies involving human subjects, the authors must explicitly state in the paper that the research received IRB approval and was conducted in accordance with the relevant standards.
Statement of informed consent: Copies of written informed consent and IRB approval for clinical research should be kept. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct.
Originality and duplicate publication: Duplicate publication or duplicate submission is prohibited in accordance with the ICMJE recommendations (https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/overlapping-publications.html). Manuscripts that have been published or are being submitted to other journal(s) should not be submitted to KJAN. Manuscripts that have been published or are currently under consideration for publication in KJAN must not be submitted to another journal. The corresponding author must obtain approval from the Editor-in-Chief of both related journals if s/he wants to reprint a published manuscript in another language.
If manuscripts have been submitted or are currently under consideration for publication in KJAN, the Editorial Board will determine the nature and degree of duplicate publication or duplicate submission for the manuscript. If a manuscript has been published in KJAN, the KSAN ethics committee will determine the nature and degree of duplication.
KJAN follows the recommendations for authorship set out by the ICMJE Authorship guidelines (http://www.icmje.org/icmje-recommendations.pdf). Authorship is attributed only to individuals who have directly participated and made significant contributions to the creation of the manuscript. Authorship should be based upon all four of the following criteria: 1) substantial contribution to the concept or design of the work, or the acquisition or analysis and interpretation of data; 2) drafting the work or revising it critically for important intellectual content; 3) final approval of the version submitted for publication; 4) accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All other contributors not listed as authors should be mentioned in the acknowledgements section.
If a manuscript is based on a master's thesis or doctoral dissertation, the author must disclose that the manuscript is the product of his/her thesis or a dissertation for an academic degree. The first author must be the recipient of the academic degree from the work presented in the manuscript.
Any changes in authorship (addition, deletion or change in order of authorship) must be approved by the Editorial Board prior to the manuscript's acceptance for publication. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason(s) for the change in the author list; and (b) written confirmation (e-mail, letter) from all authors that they agree with any addition, removal, or rearrangement.
The corresponding author will be responsible for informing the editor regarding potential conflicts of interest for all listed authors that might influence their interpretation of data. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there is no conflict of interest, this should also be explicitly stated as "The author(s) declare(s) that there is no conflict of interest."
This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors (ICMJE)” (https://doi.org/10.3346/jkms.2017.32.7.1051). All clinical trials (as defined by the International Committee of Medical Journal Editors) must be registered in a publicly accessible trial registry. For all other types of studies, including systematic reviews, prospective registration is strongly encouraged. If a study has been registered, please cite the registration number in both the abstract and body of the paper. The journal accepts registration in any of the primary registries that participate in the World Health Organization International Clinical Trials Portal (http://www.who.int/ictrp/en/), National Institutes of Health ClinicalTrials.gov (http://www.clinicaltrials.gov/), International Standard Randomized Controlled Trial Number Registry (www.ISRCTN.org), or the Clinical Research Information Service, Korea Disease Control and Prevention Agency (KDCA) (https://cris.hih.go.kr/cris/index.jsp).
This journal encourages and enables authors to share data that supports the research publication, where appropriate, and to interlink the data with other published articles. Research data refers to the results of observations or experiments that validate the research findings. To facilitate reproducibility and data reuse, this journal encourages authors to share their software, codes, models, algorithms, protocols, methods, and other useful materials related to the project. Data generated through the participation of subjects and the public should be put to maximum use by the research community and, whenever possible, translated to deliver patient benefits. Data sharing benefits numerous research-related activities: reproducing analyses, testing secondary hypotheses, developing and evaluating novel statistical methods, teaching, aiding the design of future trials and meta-analyses, and helping to prevent error, fraud, and selective reporting. To promote more transparent and reproducible research, we ask authors to submit a Data Availability Statement in the manuscript to help readers understand how they can access the data, code, and other resources that support the research findings.
The following are examples of data-sharing statements:
At submission, authors are required to disclose whether they used Artificial Intelligence (AI)-assisted technologies (such as Large Language Models [LLMs], chatbots, or image creators) in their work. Authors should describe how they used AI-assisted technologies in both the cover letter and the appropriate section of the manuscript. For example, if AI was used for writing assistance, this should be described in the Acknowledgments section. If AI was used for data collection, analysis, or figure generation, the authors should describe this use in the Methods section. Chatbots (such as ChatGPT) should not be listed as authors because they cannot be held responsible for the accuracy, integrity, and originality of the work, and these responsibilities are required for authorship. Therefore, authors are responsible for any submitted material that included the use of AI-assisted technologies. Authors should carefully review and edit AI-generated results because AI can generate authoritative-sounding output that can be incorrect, incomplete, or biased. Authors must ensure there is appropriate attribution of all quoted material, including full citations, and should not list AI and AI-assisted technologies as an author or co-author, nor cite AI as an author.
If reviewers or readers suspect publication malpractice, such as fabrication, falsification, salami slicing, plagiarism, or simultaneous/ duplicate publication, inappropriate changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the process of resolution will be initiated following the flowchart provided by the Committee on Publication Ethics (COPE, http://publicationethics.org/resources/flowcharts).
If a published manuscript is suspected of an ethics violation, the KSAN ethics committee, which includes the editor-in-chief of KJAN, will be convened. The procedure will be conducted in the following order: a preliminary investigation, a second investigation, and decision, in accordance with the prescribed regulations. If a published manuscript is determined to involve an ethics violation, members found to have violated this regulation and the general ethical principles of research will be subject to the following consequences, and other relevant matters shall be determined by the KSAN ethics committee.
KJAN publishes original articles, review articles, invited articles, and editorials.
Authors are encouraged to adhere to relevant reporting guidelines when describing their study. Reporting guidelines endorsed by the journal are listed below, from the EQUATOR network (https://www.equator-network.org/).
Observational cohort, case-control, and cross-sectional studies
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
Meta-analysis of Observational Studies in Epidemiology (MOOSE)
Qualitative studies
Consolidated Criteria for Reporting Qualitative Research (COREQ)
Standards for Reporting Qualitative Research (SRQR)
Quasi-experimental/ non-randomized trials
Transparent Reporting of Evaluations with Non-randomized Designs (TREND)
Randomized (and quasi randomized) controlled trials
Consolidated Standards of Reporting Trials (CONSORT)
Study of Diagnostic accuracy/assessment scale
Standards for the Reporting of Diagnostic Accuracy Studies (STARD)
Systematic Review and meta-analysis
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)
Meta-analysis of Observational Studies in Epidemiology (MOOSE)
Quality improvement studies
Standards for Quality Improvement Reporting Excellence (SQUIRE)
The composition of manuscripts shall be in the following order: title page, abstract and keywords, main text, references, tables and figures, and appendices. Each section begins on a new page. The main body of the manuscript (including the references, figures, tables, acknowledgements, and any funding information) should not include any identifying information, such as the authors' names or affiliations, to ensure a blind review.
Manuscripts should be submitted electronically via this journal’s submission system (https://submit.kjan.or.kr/). The first and corresponding authors should be members of KSAN, with the exception of non-Korean authors. Under certain circumstances, non-members can submit manuscripts following approval by the editorial board. All correspondence, including notification of the editor's decision and requests for revisions, will be processed via this system. Authors should complete the Submission Checklist and sign the Copyright Transfer Agreement form and submit via the submission system. For any questions regarding the use of the online system, please contact the KJAN publication director via phone, fax, or e-mail.
This journal follows a double-blind peer review process. Each submission will initially be assessed by the editors to determine suitability for publication in this journal. If a submission is deemed suitable, it will typically be sent to a minimum of three reviewers for an independent expert assessment of the scientific quality. The decision as to whether an article is accepted or rejected will be taken by our editors.
After the paper has been accepted for publication, the author(s) should submit the final version of the manuscript. The names and affiliations of the authors should be double-checked, and if the originally submitted image files were of poor resolution, higher-resolution image files should be submitted at this time. Symbols (e.g., circles, triangles, squares), letters (e.g., words, abbreviations), and numbers should be large enough to be legible on reduction to the journal’s column widths. All symbols must be defined in the fig-ure caption. If references, tables, or figures are moved, added, or deleted during the revision process, renumber them to reflect such changes so that all tables, references, and figures are cited in numeric order.
Before publication, the manuscript editor will correct the manuscript so that it meets the standard publication format. The author(s) must respond within 48 hours when the manuscript editor contacts the corresponding author for revisions. If the response is delayed, the manuscript’s publication may be postponed to the next issue.
The author(s) will receive the final version of the manuscript as a PDF file. Upon receipt, the author(s) must notify the editorial office of any errors found in the file within 48 hours. Any errors found after this time are the responsibility of the author(s) and will have to be corrected as an erratum.
To correct errors in published articles, the corresponding author should contact the journal’s editorial office with a detailed description of the proposed correction. Corrections that seriously affect the interpretation or conclusions of the article will be reviewed by the editors. Corrections will be published as an author correction or a publisher correction in a later issue of the journal.
Minor errors will be corrected directly in the online version of the article. An indication of the correction, along with the date it was made, will be added to the article information in both the HTML and PDF versions. A separate correction note will not be published.
When a manuscript is accepted for publication, an article processing charge (APC) of 600 USD (KRW 600,000) per article is charged to the corresponding author.
All manuscripts published in KJAN are protected by copyright. The copyright and transfer rights of the digital content of the published paper and journal are owned by the KSAN. Copyright Transfer Agreement form should be submitted online at submission. All authors should print their names and sign the copyright transfer agreement.
KJAN is an open-access journal. Articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives 4.0 (CC BY-NC-ND 4.0) license, which permits copying and distributing the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the KJAN.
All manuscripts published in KJAN are freely available through open access to read and download from any electronic link, including those found on the KJAN website (http://www.kjan.or.kr/) immediately and permanently after publication.
History:
Enacted Jun, 1994 | Revised Aug, 2010 |
Revised Dec, 1999 | Revised Jun, 2012 |
Revised Dec, 2002 | Revised Jul, 2014 |
Revised Dec, 2003 | Revised Aug, 2016 |
Revised Dec, 2006 | Revised Feb, 2018 |
Revised Dec, 2007 | Revised Aug, 2018 |
Revised Jun, 2008 | Revised Dec, 2018 |
Revised Dec, 2008 | Revised Jun, 2020 |
Revised Feb, 2009 | Revised Mar, 2023 |
Revised Jun, 2009 | Revised Aug, 2023 |
Revised Apr, 2010 | Revised May, 2025 |